# Safety Study of Vx006 Vaccine in Solid Tumor Patients

> **NCT02289196** · PHASE1 · COMPLETED · sponsor: **Vaxon Biotech** · enrollment: 23 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Vx-006: 0,5mg
- **DRUG:** Vx-006: 1mg
- **DRUG:** Vx-006: 5mg
- **DRUG:** Vx-006: 10mg

## Key facts

- **NCT ID:** NCT02289196
- **Lead sponsor:** Vaxon Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-10
- **Final completion:** 2017-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289196, "Safety Study of Vx006 Vaccine in Solid Tumor Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02289196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*